Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 7/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.42 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264779 | 0.92 | P2RX3 (0.47) | P2RX3P2RX4P2RX1P2RX2ENTPD1 | |
| SCHEMBL264918 | 0.83 | DNPH1 (0.42) | P2RX3P2RX4P2RX1ENTPD1RNASEL | |
| SCHEMBL264096 | 0.81 | GPR17 (0.43) | P2RX3P2RX4P2RX1P2RX2ENTPD1 | |
| SCHEMBL10182407 | 0.78 | CA12 (0.41) | — | |
| SCHEMBL12261199 | 0.72 | P2RX1 (0.46) | P2RX3P2RX4P2RX1P2RX2ENTPD1 | |
| SCHEMBL264091 | 0.72 | ADORA2A (0.48) | SMN1; SMN2 | |
| SCHEMBL13847085 | 0.72 | ADORA2A (0.48) | SMN1; SMN2 | |
| SCHEMBL4962425 | 0.72 | ADORA2A (0.48) | SMN1; SMN2 | |
| SCHEMBL14071995 | 0.72 | P2RY1 (0.41) | P2RX3P2RX4P2RX1P2RX2P2RY1 | |
| SCHEMBL264550 | 0.72 | CA12 (0.33) | ENTPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | P2RX3 1147/4885P2RX4 1188/4885P2RX1 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.